Genomind is a King of Prussia, PA‑based genetic testing company advancing precision mental health care. Its core product, the Genecept Assay™, is a cheek‑swab genetic test that analyzes key genes selected from hundreds of studies to help clinicians optimize treatment decisions. The assay is used to guide treatment for conditions including depression, anxiety, ADHD, bipolar disorder, PTSD and schizophrenia. Peer‑reviewed published studies cited by the company report that the test can improve patient outcomes and reduce overall medical costs. Genomind closed a $6M financing round led by Claritas Capital and will use the funds to support continued growth, run a multi‑site randomized controlled trial of the Genecept Assay, and develop an expanded product. The company is led by President and CEO Michael Koffler; Claritas had previously led a $5M investment in April 2014. Genomind provides the Genecept™ Assay, a saliva-based genetic test that helps inform treatment decisions for patients with depression and other psychiatric disorders. The assay includes a proprietary panel of biomarker tests, an analytic report and a psychopharmacologist consultation. It can be used across a range of psychiatric conditions, including depression, bipolar disorder, schizophrenia, anxiety disorders, autism, OCD and ADHD. The company reports its test is used by clinicians and patients in all 50 states. Genomind is led by Co-Founder and Chairman Dr. Ronald I. Dozoretz, Co-Founder Jay Lombard, DO, and President and CEO Scott A. Storrer. The company said it will use new funding to grow operations and products.

Total raised

$11M

Funding rounds

2

Latest round

Equity

Latest activity

Sep 2015